Stay updated with breaking news from Greg Mckee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
San Diego, California--(Newsfile Corp. - June 1, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing compounds for diseases with unmet
From brand new supervisors to C-suite executives, growth ensures leaders are maximizing their effectiveness and preparing for the future.
Tryp Therapeutics new CEO looking to take big steps this year with a number of partnerships Tryp Therapeutics (CSE: TRYP- OTCQB: TRYPF) CEO Greg McKee joined Steve Darling from Proactive to talk about his new role as Chairman and CEO. McKee talks about his background and what he sees moving forward for the company. McKee telling Proactive about some of their drugs in the pipeline and how close they are to clinical trial stage. This include Psilocybin-for-Neuropsychiatric Disorders targeting chronic pain and eating disorders. We also get an update on razoxane with his designed for soft tiss...
Tryp Therapeutics Inc.: Tryp Therapeutics Announces Q2 2021 Financial Results Tryp" or the " Company"), today announced its interim financial results for the three and six month periods ended February 28, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com. The reported period included the completion of Tryp's Initial Public Offering; significant additions to the Company's executive ...
Subscription Notification We have noticed that there is an issue with your subscription billing details. Please update your billing details here Please update your billing information The subscription details associated with this account need to be updated. Please update your billing details here to continue enjoying your subscription. Your subscription will end shortly Please update your billing details here to continue enjoying your access to the most informative and considered journalism in the UK.